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Lipoprotein abnormalities in diabetic nephropathy. ent when diabetic nephropathy is present [5]. These ab-
Background. The risk of death from coronary heart disease normal plasma lipoproteins may contribute to the in-
(CHD) is substantially increased in diabetic nephropathy com- creased CHD risk in diabetic nephropathy.pared with normal subjects or diabetes without nephropathy.
I tried to define abnormal plasma lipoproteins profiles contrib-
uting to the increased CHD risk in diabetic nephropathy. This
PLASMA TRIGLYCERIDE LEVELS INstudy included: middle-aged to older type 2 diabetic patients
TYPE 2 DIABETES WITH ANDwith normoalbuminuria, microalbuminuria, and overt albumin-
uria; nondiabetic patients with primary renal disease; and nor- WITHOUT NEPHROPATHY
mal control subjects.
It has been well established that plasma TG levelsResults. Triglyceride (TG) levels were significantly in-
are increased in patients with type 2 diabetes. However,creased in type 2 diabetic patients with microalbuminuria and
overt proteinuria. Glycemic control or insulin resistance were diabetic nephropathy including the microalbuminuric
not associated with TG levels. Intermediate-density lipoprotein stage might be involved in the mechanisms for elevating
(IDL) and remnant-like particle (RLP) cholesterol in type plasma TG, as was suggested in type 1 diabetes mellitus2 diabetics were significantly elevated in patients with overt
[6]. Therefore, we measured plasma TG levels in middle-nephropathy. Hepatic TG lipase (HTGL) was significantly de-
aged to older type 2 diabetic patients with normoalbumi-creased in diabetic nephropathy, and their higher IDL levels
were inversely related to decreased HTGL. Low-density lipo- nuria, microalbuminuria and overt albuminuria, and
protein (LDL) size was significantly smaller in diabetic ne- compared these patients with age- and weight-matched
phropathy compared with nondiabetics with kidney disease.
nondiabetic controls. As shown in Figure 1, plasma TGThe TG response after the oral fat load was significantly greater
levels in normoalbuminuric diabetics were identical toin diabetic nephropathy, and the LDL size was inversely associ-
ated with the magnitude of postprandial lipemia. Microalbumi- those in nondiabetic controls, whereas TG levels were
nuric diabetic patients had a lower lipoprotein lipase (LPL) significantly increased in non–insulin-dependent diabe-
mass and a higher von Willebrand factor (vWF), an indicator tes mellitus (NIDDM) with microalbuminuria and overt
of endothelial cell damage, than normoalbuminuric patients.
proteinuria. No significant difference in plasma TG levelsThe LPL mass was inversely associated with vWF, suggesting
was observed between good, fair, and poor glycemicthat widespread endothelial cell damage results in a reduction
in LPL bound to endothelium in diabetic subjects with microal- control groups if the degree of albuminuria was identical.
buminuria. Multiple regression analysis revealed that the amount of
Conclusions. Plasma lipoprotein profiles become more ath-
albuminuria was related to TG levels, independent oferogenic in patients with diabetic nephropathy, including the
body mass index, HbA1c, or steady-state plasma glucosesubclinical stage, compared with diabetics without nephropathy
or those with nondiabetic kidney disease. (SSPG) levels when glucose, insulin, and octreotide were
continuously infused. These results suggest that diabetic
nephropathy, including the subclinical stage, plays a criti-
The risk of death from coronary heart disease (CHD) cal role in the hypertriglyceridemia (HTG) associated
is substantially increased in diabetic nephropathy com- with type 2 diabetes mellitus. Poor glycemic control or
pared with normal subjects or diabetes without nephrop- insulin resistance are not significantly associated with
athy [1–3]. Increased levels of triglyceride (TG)-rich lipo- the HTG, at least in middle-aged and older Japanese
proteins (TGRL), including remnant lipoproteins and type 2 diabetic patients.
decreased high-density lipoprotein (HDL), have been
frequently reported in patients with diabetes [3–5], and
REMNANT LIPOPROTEINSthis atherogenic lipoprotein profile becomes more appar-
Although it has been reported that atherogenic lipo-
protein remnants are usually increased in patients withKey words: diabetes, triglyceride-rich proteins, remnants, small dense
LDL. diabetes, the influence of diabetic nephropathy on rem-
nants is poorly understood. We measured intermediate- 1999 by the International Society of Nephrology
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there was an inverse correlation between LDL size and
plasma TG levels, when HTG subjects were excluded,
their LDL size became comparable to those in controls.
On the other hand, LDL size was still smaller in diabetic
nephropathy even when HTG subjects were excluded
(Fig. 2).
Fasting plasma TG concentrations are usually corre-
lated with the degree of postprandial lipemia. However,
differences in fasting TG levels only partially account for
the individual variation in the magnitude of postprandial
lipemia. Because LDL size is strongly regulated by
plasma TG levels, LDL composition and size might be
influenced by the postprandial TG levels rather than the
fasting levels. We performed an oral fat load test in
normotriglyceridemic subjects (fasting TG , 1.7 mm)
of control, diabetes with and without nephropathy andFig. 1. Plasma triglyceride concentrations in type 2 diabetic patients
without and with nephropathy. Data represent mean 6 sem. aP , 0.05 primary renal disease [8]. The TG responses in plasma
vs. controls by analysis of variance. Abbreviations are: DM, diabetes and TGRL after the oral fat load were significantlymellitus; micro, microalbuminuria; overt, overt proteinuria.
greater in diabetes with nephropathy compared with
controls or diabetes without nephropathy, whereas such
a marked postprandial lipemia was not observed in pa-
density lipoprotein (IDL, d 5 1.006 to 1.019) and rem- tients with primary renal disease. LDL size was signifi-
nant-like particle (RLP) cholesterol in type 2 diabetics cantly inversely correlated with postprandial TG re-
with various degrees of nephropathy and nondiabetic sponses, which was independent on fasting TG levels.
uremic patients receiving hemodialysis (HD). IDL-TG These results suggest that postprandial lipemia may play
and IDL-cholesterol were comparable between control
an important role in reducing LDL particle size in pa-subjects and normoalbuminuric diabetic patients, whereas
tients with diabetic nephropathy.these concentrations were significantly elevated in pa-
tients with diabetic nephropathy, including the microal-
buminuric stage. IDL-apoB and RLP cholesterol were LIPOPROTEIN LIPASE AND
markedly increased in diabetics with overt nephropathy ENDOTHELIAL DAMAGE
and chronic renal failure. Both diabetic and nondiabetic Plasma TG concentration is significantly increased
HD patients showed substantially increased IDL levels, even in the early stage of diabetic nephropathy. The
and these values were almost identical. Hepatic TG li- mechanism for HTG in microalbuminuric diabetic sub-
pase (HTGL) activity in post-heparin plasma was sig- jects must be different from that in nephrotic syndrome
nificantly decreased in HD patients, and their higher because the amount of urinary albumin excretion is too
IDL levels were inversely related to decreased HTGL
small to reduce the plasma albumin concentration. Deck-activity. Therefore, HTGL may play an important role
ert et al proposed the hypothesis that microalbuminuriain dyslipidemia in diabetic nephropathy, especially in
in diabetic patients may reflect widespread vascular dam-uremic cases.
age [9]. Moreover, they speculated that lipoprotein lipase
(LPL) attached to the surface of endothelium is de-SMALL, DENSE LOW-DENSITY LIPOPROTEIN
creased by the generalized endothelial cell damage,AND POSTPRANDIAL LIPEMIA
thereby causing HTG in diabetic subjects with microal-Epidemiological studies suggest that a predominance
buminuria. To elucidate this possibility, we measuredof the smaller and less dense low-density lipoprotein
heparin-releasable LPL mass and plasma von Wille-(LDL) particles is a new risk factor of CHD. We found
brand factor (vWF), a marker for generalized endothelialthat LDL particle diameter was significantly smaller in
damage, in type 2 diabetic patients with and withouttype 2 diabetic patients with nephropathy compared with
microalbuminuria [10]. Microalbuminuric patients haddiabetics without nephropathy or nondiabetic controls
lower LPL mass than normoalbuminuric patients, and[7]. To determine whether kidney damage/renal dysfunc-
the LPL mass was inversely correlated with TGs andtion are associated with the formation of small dense
positively with HDL cholesterol levels, suggesting thatLDL, we measured LDL particle size in patients with
this enzyme plays a critical role in dyslipidemia associ-primary renal disease and nondiabetic HD patients [8].
ated with the early stage of diabetic nephropathy. TheHD patients did not have small, dense LDL, whereas
heparin-releasable LPL mass was inversely associatedLDL size in patients with primary renal disease was
smaller than those in controls (Fig. 2). However, because with vWF, which supports the hypothesis that wide-
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Fig. 2. Comparison of low-density lipopro-
tein (LDL) particle diameter between con-
trols (Cont), type 2 diabetic patients (DM)
with various degrees of albuminuria, and pri-
mary renal disease patients (PRD). Data rep-
resent mean 6 sem. Hemodialysis (HD) and
PRD patients received hemodialysis. aP , 0.05
vs. controls; bP , 0.05 vs. normoalbuminuric
DM; cP , 0.05 vs. PRD without HD; dP ,
0.05 vs. PRD with HD, by analysis of variance.
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